{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T23:44:41Z","timestamp":1786146281808,"version":"build-2736575974"},"reference-count":17,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.clbc.2026.06.004","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:21:55Z","timestamp":1781652115000},"page":"1-6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["COVID-19 as a Catalyst for Ultra-Hypofractionated Radiotherapy in Early Breast Cancer: Trends, Predictors, and Estimated Cost Savings"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6363-556X","authenticated-orcid":false,"given":"Riley","family":"McDougall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangyang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared","family":"Robbins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lora","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2026.06.004_bib0001","unstructured":"USCS data visualizations. n.d. Available at: https:\/\/gis.cdc.gov\/grasp\/USCS\/DataViz.html Accessed: February 11, 2026."},{"key":"10.1016\/j.clbc.2026.06.004_bib0002","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.prro.2014.06.003","article-title":"Choosing wisely: the American Society for Radiation Oncology\u2019s top 5 list","volume":"4","author":"Hahn","year":"2014","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.clbc.2026.06.004_bib0003","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1245\/s10434-007-9747-3","article-title":"The National Cancer Data Base: a powerful initiative to improve cancer care in the United States","volume":"15","author":"Bilimoria","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clbc.2026.06.004_bib0004","unstructured":"Physician fee schedule. CMS n.d. Available at: https:\/\/www.cms.gov\/medicare\/payment\/fee-schedules\/physician Accessed: February 11, 2026."},{"key":"10.1016\/j.clbc.2026.06.004_bib0005","unstructured":"IBM SPSS Statistics for Windows (Version 29.0.2) [Computer software]. IBM Corp. 2023."},{"key":"10.1016\/j.clbc.2026.06.004_bib0006","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S1470-2045(13)70386-3","article-title":"The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials","volume":"14","author":"Haviland","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2026.06.004_bib0007","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1056\/NEJMoa0906260","article-title":"Long-term results of hypofractionated radiation therapy for breast cancer","volume":"362","author":"Whelan","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2026.06.004_bib0008","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1200\/JCO.19.02750","article-title":"Ten-year results of FAST: a randomized controlled trial of 5-fraction whole-breast radiotherapy for early breast cancer","volume":"38","author":"Brunt","year":"2020","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.clbc.2026.06.004_bib0009","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/S0140-6736(20)30932-6","article-title":"Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial","volume":"395","author":"Murray Brunt","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.clbc.2026.06.004_bib0010","unstructured":"Guidelines detail. NCCN n.d. Available at: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1419 Accessed: February 11, 2026."},{"key":"10.1016\/j.clbc.2026.06.004_bib0011","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1200\/JCO.20.00650","article-title":"Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-Florence Trial","volume":"38","author":"Meattini","year":"2020","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.clbc.2026.06.004_bib0012","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.clon.2020.03.006","article-title":"International guidelines on radiation therapy for breast cancer during the COVID-19 pandemic","volume":"32","author":"Coles","year":"2020","journal-title":"Clin Oncol R Coll Radiol G B"},{"key":"10.1016\/j.clbc.2026.06.004_bib0013","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.adro.2020.03.013","article-title":"Breast radiation therapy under COVID-19 Pandemic resource constraints\u2014approaches to defer or shorten treatment from a comprehensive cancer center in the United States","volume":"5","author":"Braunstein","year":"2020","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.clbc.2026.06.004_bib0014","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ijrobp.2012.12.015","article-title":"A population-based study of the fractionation of postlumpectomy breast radiation therapy","volume":"86","author":"Ashworth","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clbc.2026.06.004_bib0015","article-title":"Trends in radiation oncology treatment fractionation at a single academic center, 2010 to 2020","volume":"7","author":"Cher","year":"2022","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.clbc.2026.06.004_bib0016","article-title":"Use of radiation therapy for the treatment of breast cancer in 2019 versus 2020","volume":"9","author":"Powell","year":"2024","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.clbc.2026.06.004_bib0017","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1016\/S0140-6736(23)00619-0","article-title":"Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial","volume":"401","author":"Coles","year":"2023","journal-title":"Lancet"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820926000893?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820926000893?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T23:32:30Z","timestamp":1786145550000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820926000893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":17,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1526820926000893"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2026.06.004","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"COVID-19 as a Catalyst for Ultra-Hypofractionated Radiotherapy in Early Breast Cancer: Trends, Predictors, and Estimated Cost Savings","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2026.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}